financetom
Business
financetom
/
Business
/
Sealed Air beats Q3 sales expectations, raises 2025 profit outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sealed Air beats Q3 sales expectations, raises 2025 profit outlook
Nov 4, 2025 4:04 AM

Overview

* Sealed Air ( SEE ) Q3 net sales rise slightly, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, rising 10% yr/yr

* Company raises 2025 outlook for adjusted EBITDA and EPS

Outlook

* Sealed Air ( SEE ) raises 2025 Adjusted EBITDA outlook to $1,120-$1,140 mln

* Company increases 2025 Adjusted EPS forecast to $3.25-$3.35

* Sealed Air ( SEE ) maintains 2025 sales forecast at $5,275-$5,325 mln

Result Drivers

* OPERATING LEVERAGE - Improved operating leverage and favorable tax resolutions contributed to higher net earnings and EPS

* PRODUCTIVITY INITIATIVES - Adjusted EBITDA and EPS increased due to ongoing execution of productivity initiatives and operational discipline

* VOLUME STABILIZATION - Protective volume stabilization and transformation initiatives contributed to margin expansion

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Beat $1.35 $1.31

sales bln bln (11

Analysts

)

Q3 Beat $0.87 $0.70

Adjusted (14

EPS Analysts

)

Q3 EPS $1.26

Q3 Net $186 mln

Income

Q3 $184.70

Operatin mln

g profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

* Wall Street's median 12-month price target for Sealed Air Corp ( SEE ) is $41.45, about 18% above its November 3 closing price of $33.98

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Norges Bank Investment Management backs Disney in board room fight with hedge funds
Norges Bank Investment Management backs Disney in board room fight with hedge funds
Apr 2, 2024
NEW YORK, April 2 (Reuters) - Norges Bank Investment Management, one of Walt Disney's ( DIS ) biggest investors, said on Tuesday that it voted to re-elect the entertainment giant's directors, dealing a blow to the hedge funds pushing for seats on Disney's ( DIS ) board. NBIM, which manages the Norwegian Government Pension Fund and owned a 1.2% stake...
Cielo's controlling shareholders reach deal to lift tender offer price
Cielo's controlling shareholders reach deal to lift tender offer price
Apr 2, 2024
SAO PAULO, April 2 (Reuters) - The controlling shareholders of Brazilian payments firm Cielo have reached an agreement with some minority shareholders to raise the price of a tender offer to take the company private, according to a securities filing on Tuesday. Under the agreement, lenders Banco do Brasil and Bradesco have committed to raise the offer price to 5.60...
Avicanna's Q4 Loss Narrows, Revenue Grows
Avicanna's Q4 Loss Narrows, Revenue Grows
Apr 2, 2024
08:18 AM EDT, 04/02/2024 (MT Newswires) -- Avicanna Inc. ( AVCNF ) , a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, on Tuesday reported a fourth-quarter net comprehensive loss of $2.4 million, or $0.02 per share, narrower than a loss of $7.8 million, or $0.09 per share, a year earlier. Revenue for the quarter...
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell
Apr 2, 2024
08:17 AM EDT, 04/02/2024 (MT Newswires) -- Verve Therapeutics ( VERV ) said Tuesday it paused enrollment for its Heart-1 phase 1b clinical trial after one of its dosed patients experienced serious adverse events. Shares of the company fell more than 34% in recent premarket activity on Tuesday. The Heart-1 trial is an open-label phase 1b trial designed to evaluate...
Copyright 2023-2026 - www.financetom.com All Rights Reserved